Fulgent Genetics forecasts $350M 2026 revenue and 53% AP growth as Bako, StrataDx acquisitions reshape customer mix
Source: SeekingAlpha
2026-02-27 18:08:36 ET
More on Fulgent Genetics
- Fulgent Genetics, Inc. (FLGT) Q4 2025 Earnings Call Transcript
- Fulgent Genetics: The Price Has Caught Up To Value, But I Still Like The Stock
- Fulgent Genetics: From Genetic Code To Cancer Cure - Why I Assign A Hold Rating
- Fulgent Genetics Non-GAAP EPS of $0.16 beats by $0.13, revenue of $83.3M misses by $2.08M
- Fulgent Genetics Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Fulgent Genetics forecasts $350M 2026 revenue and 53% AP growth as Bako, StrataDx acquisitions reshape customer mix
Fulgent Genetics Inc.
NASDAQ: FLGT
FLGT Trading
0.72% G/L:
$14.635 Last:
324,061 Volume:
$14.41 Open:
FLGT Latest News
February 12, 2026 07:30:00 am
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
FLGT Stock Data
$726,441,212
20,677,299
5.21%
56
N/A
Medical Diagnostics & Screening
Healthcare
US
El Monte
